Next Article in Journal
Thermosensitive Nanosystems Associated with Hyperthermia for Cancer Treatment
Next Article in Special Issue
Iron as Therapeutic Target in Human Diseases
Previous Article in Journal
Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents
Previous Article in Special Issue
What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron
Open AccessReview

Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis

1
Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Brisbane, Queensland 4059, Australia
2
School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, Queensland 4059, Australia
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(4), 170; https://doi.org/10.3390/ph12040170
Received: 7 October 2019 / Revised: 15 November 2019 / Accepted: 19 November 2019 / Published: 25 November 2019
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
The interaction between hepcidin and ferroportin is the key mechanism involved in regulation of systemic iron homeostasis. This axis can be affected by multiple stimuli including plasma iron levels, inflammation and erythropoietic demand. Genetic defects or prolonged inflammatory stimuli results in dysregulation of this axis, which can lead to several disorders including hereditary hemochromatosis and anaemia of chronic disease. An imbalance in iron homeostasis is increasingly being associated with worse disease outcomes in many clinical conditions including multiple cancers and neurological disorders. Currently, there are limited treatment options for regulating iron levels in patients and thus significant efforts are being made to uncover approaches to regulate hepcidin and ferroportin expression. These approaches either target these molecules directly or regulatory steps which mediate hepcidin or ferroportin expression. This review examines the current status of hepcidin and ferroportin agonists and antagonists, as well as inducers and inhibitors of these proteins and their regulatory pathways. View Full-Text
Keywords: iron metabolism; hepcidin; iron homeostasis; ferroportin iron metabolism; hepcidin; iron homeostasis; ferroportin
Show Figures

Figure 1

MDPI and ACS Style

Hawula, Z.J.; Wallace, D.F.; Subramaniam, V.N.; Rishi, G. Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis. Pharmaceuticals 2019, 12, 170.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop